By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.
Histologically proven first diagnosis of cHL
Stage I-II without risk factors
Large mediastinal mass
Extranodal involvement
Central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma,
Prior cHL-directed treatment
Prior chemotherapy, RT or allogeneic stem cell/solid organ transplant
Prior or concurrent disease precluding protocol treatment (for details see section 4.2)
Single group
Pembrolizumab
Drug6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by radiotherapy 20Gy
Progression Free Survival
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
